-       Report 
- June 2021
-  77 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- May 2024
-  90 Pages 
- United States 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- April 2024
-  169 Pages 
- Global 
   From       €2236EUR$2,500USD£1,967GBP 
          -       Report 
- April 2023
-  115 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
          -       Report 
- February 2024
-  109 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
                The Oligonucleotide Therapeutics market is a subset of the Pharmaceuticals industry. It is focused on the development and commercialization of oligonucleotide-based drugs, which are used to treat a variety of diseases. These drugs are designed to target specific genetic sequences, allowing for more precise and effective treatments. Oligonucleotide Therapeutics are used to treat a range of conditions, including cancer, cardiovascular disease, neurological disorders, and infectious diseases.
The    Oligonucleotide Therapeutics market is growing rapidly, driven by advances in gene-editing technology and the increasing prevalence of genetic diseases. This has led to increased investment in the development of new drugs and therapies, as well as increased demand for existing treatments.
Some of the major players in the Oligonucleotide Therapeutics market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Moderna Therapeutics, and Arrowhead Pharmaceuticals. Show Less   Read more